As pressure mounts to develop a successful Covid-19 vaccine, Food and Drug Administration Commissioner Stephen Hahn insisted any agency approval would “adhere to standards” that ensure safety and effectiveness. But Hahn left the door open to a so-called emergency use authorization, raising concerns the FDA might still face political pressure to approve a vaccine before the November elections.

His remarks appeared late Wednesday in an op-ed in The Washington Post just as nearly 400 health experts and scientists released an open letter that was sent to Hahn and urged a “transparent and rigorous FDA approval process that is devoid of political considerations.” The letter was organized by the Center for Science in the Public Interest.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Great closing quote – “but this approach would simply be warped” – sounds very realistic to me.

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy